Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ACP-196

Known as: Bruton Tyrosine Kinase Inhibitor ACP-196 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
BACKGROUND Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly… Expand
Highly Cited
2017
Highly Cited
2017
Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
2017
2017
Acalabrutinib is a new, irreversible Bruton tyrosine kinase (BTK) inhibitor, reported to be more selective than ibrutinib.[1][1… Expand
  • figure 1
  • figure 2
  • figure 3
Review
2017
Review
2017
Immunotherapy is becoming an accepted treatment modality for many patients with cancer and is now approved for use in platinum… Expand
  • table 1
  • figure 1
  • table 2
Highly Cited
2016
Highly Cited
2016
BACKGROUND Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Review
2016
Review
2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class… Expand
  • table 1
  • table 2
Review
2016
Review
2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis… Expand
  • figure 1
  • table 1
Highly Cited
2016
Highly Cited
2016
Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
4130Background: The importance of the tumor microenvironment in the biology of mPC has been increasingly recognized. However… Expand
2015
2015
Ibrutinib, a first generation Btk inhibitor, is approved for the treatment of CLL and mantle cell lymphoma; known toxicities… Expand